Engelstaedter, Verena, Heublein, Sabine, Schumacher, Anamur Lan, Lenhard, Miriam, Engelstaedter, Helen, Andergassen, Ulrich, Guenthner-Biller, Margit, Kuhn, Christina, Rack, Brigitte, Kupka, Markus, Mayr, Doris and Jeschke, Udo ORCID: 0000-0003-2623-3235 (2012). Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients. BMC Cancer, 12. LONDON: BMC. ISSN 1471-2407

Full text not available from this repository.

Abstract

Background: Mucin-1 is known to be over-expressed by various human carcinomas and is shed into the circulation where it can be detected in patient's serum by specific anti-Mucin-1 antibodies, such as the tumour marker assays CA 15-3 and CA 27.29. The prognostic value of Mucin-1 expression in ovarian carcinoma remains uncertain. One aim of this study was to compare the concentrations of Mucin-1 in a cohort of patients with either benign or malignant ovarian tumours detected by CA 15-3 and CA 27.29. Another aim of this study was to evaluate Mucin-1 expression by immunohistochemistry in a different cohort of ovarian carcinoma patients with respect to grade, stage and survival. Methods: Patients diagnosed with and treated for ovarian tumours were included in the study. Patient characteristics, histology including histological subtype, tumour stage, grading and follow-up data were available from patient records. Serum Mucin-1 concentrations were measured with ELISA technology detecting CA 15-3 and CA 27.29, Mucin-1 tissue expression was determined by immunohistochemistry using the VU4H5 and VU3C6 anti-Mucin-1 antibodies. Statistical analysis was performed by using SPSS 18.0. Results: Serum samples of 118 patients with ovarian tumours were obtained to determine levels of Mucin-1. Median CA 15-3 and CA 27.29 concentrations were significantly higher in patients with malignant disease (p < 0.001) than in patients with benign disease. Paraffin-embedded tissue of 154 patients with ovarian carcinoma was available to determine Mucin-1 expression. The majority of patients presented with advanced stage disease at primary diagnosis. Median follow-up time was 11.39 years. Immunohistochemistry results for VU4H5 showed significant differences with respect to tumour grade, FIGO stage and overall survival. Patients with negative expression had a mean overall survival of 9.33 years compared to 6.27 years for patients with positive Mucin-1 expression. Conclusions: This study found significantly elevated Mucin-1 serum concentrations in ovarian carcinoma patients as compared to those women suffering from benign ovarian diseases. However, it needs to be noted that Mucin-1 concentrations in carcinoma patients showed a rather high variability. Results from immunohistochemistry indicate that Mucin-1 has a prognostic relevance in ovarian carcinomas when evaluating the expression by VU4H5 antibody.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Engelstaedter, VerenaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heublein, SabineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schumacher, Anamur LanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lenhard, MiriamUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Engelstaedter, HelenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Andergassen, UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Guenthner-Biller, MargitUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuhn, ChristinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rack, BrigitteUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kupka, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mayr, DorisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jeschke, UdoUNSPECIFIEDorcid.org/0000-0003-2623-3235UNSPECIFIED
URN: urn:nbn:de:hbz:38-476568
DOI: 10.1186/1471-2407-12-600
Journal or Publication Title: BMC Cancer
Volume: 12
Date: 2012
Publisher: BMC
Place of Publication: LONDON
ISSN: 1471-2407
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
MONOCLONAL-ANTIBODIES; BREAST-CANCER; MUC1; EXPRESSION; CHEMOTHERAPY; CA27.29; CA-15-3; CA15-3; ASSAYS; BRMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/47656

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item